ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,868.55
      -0.22%
      US Tech 100
      20,469.04
      0.10%
      Dow Jones
      42,392.27
      -0.36%
      Brent Oil
      76.08
      0.30%
      Bitcoin
      96,906.86
      0.01%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Australia
      5. ASX

      6. Clinuvel Pharmaceuticals Limited (CUV) Quote

      Clinuvel Pharmaceuticals Limited

      Clinuvel Pharmaceuticals Limited (CUV)

      CUV Ventures Corp
      11.98
      -0.01
      ( -0.08% )
      Updated: 22:58:50
      Delayed by 20 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      11.98
      Bid
      11.97
      Ask
      11.98
      Volume
      74,641
      11.81 Day's Range 12.02
      11.715 52 Week Range 17.71
      Market Cap
      600.243M
      Previous Close
      11.99
      Open
      11.92
      Last Trade
      13
      @
      11.98
      Last Trade Time
      22:58:50
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      97,135
      Shares Outstanding
      50,103,765
      Dividend Yield
      -
      PE Ratio
      16.83
      Earnings Per Share (EPS)
      0.71
      Revenue
      88.74M
      Net Profit
      35.64M

      About Clinuvel Pharmaceuticals Limited

      Sector
      Medicinal Chems,botanicl Pds
      Industry
      Drugs-health R&d/testing Labs
      Website
      www.clinuvel.com
      Headquarters
      Melbourne, Victoria, Aus
      Founded
      2000
      Clinuvel Pharmaceuticals Limited is listed in the Medicinal Chems,botanicl Pds sector of the Australian Stock Exchange with ticker CUV. The last closing price for Clinuvel Pharmaceuticals was AUD11.99. Over the last year, Clinuvel Pharmaceuticals shares have traded in a share price range of AUD 11.715 to AUD 17.71.

      Clinuvel Pharmaceuticals currently has 50,103,765 shares outstanding. The market capitalization of Clinuvel Pharmaceuticals is AUD600.74 million. Clinuvel Pharmaceuticals has a price to earnings ratio (PE ratio) of 16.83.

      Ask ADVFN Intelligence (AI)

      CUV Latest News

      More News

      Europe Approves Novel Australian Drug Developed for Rare Sun Disease

      The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA...

      October 24 2014
      Business Wire

      Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study

      Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study Primary endpoint shows a strong statistical trend in pain-free exposure following the treatment of the 'orphan...

      November 11 2013
      PR Newswire (US)

      Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide)

      Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has submitted a marketing authorisation application (MAA) for its first-in-class...

      February 06 2012
      Business Wire

      Clinuvel announces positive results of first Phase II US study of SCENESSE® in orphan disease erythropoietic protoporphyria ...

      Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY), a global biopharmaceutical company with unique expertise on the interaction of light and human skin...

      November 03 2011
      Business Wire

      EMA acknowledges Clinuvel’s novel drug filing in Europe in 2011

      Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it held a constructive Pre-Submission Meeting with the European Medicines Agency...

      May 12 2011
      Business Wire

      Successful Drug Trial Results for Light Intolerant 'Shadow Jumpers'

      A new Australian drug has been shown to assist in protecting patients with a rare genetic disorder that makes their skin toxic to light and UV, and previously forced them to...

      July 13 2010
      Business Wire

      Clinuvel Unveils SCENESSE® Following European Brand Approval

      Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the European Medicines Agency (EMA) Name Review Group (NRG) and the Agency’s...

      May 18 2010
      Business Wire

      Preliminary Results in Clinuvel’s Phase III Porphyria Trial

      Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has obtained promising 4-months results in testing afamelanotide in a multicentre...

      December 21 2009
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.16-1.3179571663912.1412.511.818126812.14150851DE
      4-0.92-7.1317829457412.913.311.71513255712.32962614DE
      12-2.02-14.42857142861414.8611.7159713513.10102014DE
      26-3.28-21.49410222815.2617.7111.7159112713.98558154DE
      52-4.03-25.171767645216.0117.7111.7159665914.47923019DE
      156-15.72-56.750902527127.729.3911.71510112217.57173529DE
      260-16.36-57.727593507428.3444.6711.71512285221.53048028DE

      CUV - Frequently Asked Questions (FAQ)

      What is the current Clinuvel Pharmaceuticals share price?
      The current share price of Clinuvel Pharmaceuticals is AUD 11.98
      How many Clinuvel Pharmaceuticals shares are in issue?
      Clinuvel Pharmaceuticals has 50,103,765 shares in issue
      What is the market cap of Clinuvel Pharmaceuticals?
      The market capitalisation of Clinuvel Pharmaceuticals is AUD 600.74M
      What is the 1 year trading range for Clinuvel Pharmaceuticals share price?
      Clinuvel Pharmaceuticals has traded in the range of AUD 11.715 to AUD 17.71 during the past year
      What is the PE ratio of Clinuvel Pharmaceuticals?
      The price to earnings ratio of Clinuvel Pharmaceuticals is 16.83
      What is the cash to sales ratio of Clinuvel Pharmaceuticals?
      The cash to sales ratio of Clinuvel Pharmaceuticals is 6.76
      What is the reporting currency for Clinuvel Pharmaceuticals?
      Clinuvel Pharmaceuticals reports financial results in AUD
      What is the latest annual turnover for Clinuvel Pharmaceuticals?
      The latest annual turnover of Clinuvel Pharmaceuticals is AUD 88.74M
      What is the latest annual profit for Clinuvel Pharmaceuticals?
      The latest annual profit of Clinuvel Pharmaceuticals is AUD 35.64M
      What is the registered address of Clinuvel Pharmaceuticals?
      The registered address for Clinuvel Pharmaceuticals is LEVEL 11, 535 BOURKE STREET, MELBOURNE, VICTORIA, 3000
      What is the Clinuvel Pharmaceuticals website address?
      The website address for Clinuvel Pharmaceuticals is www.clinuvel.com
      Which industry sector does Clinuvel Pharmaceuticals operate in?
      Clinuvel Pharmaceuticals operates in the DRUGS-HEALTH R&D/TESTING LABS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      IBGIronbark Zinc Limited
      AUD 0.245
      (8,066.67%)
      		91.63k
      KATOKatana Capital
      AUD 0.003
      (200.00%)
      		77.1k
      CCOOAThe Calmer Co International Ltd
      AUD 0.002
      (100.00%)
      		483.33k
      TTMOTitan Minerals Limited
      AUD 0.03
      (87.50%)
      		12.33k
      EELENRG Elements Ltd
      AUD 0.0015
      (50.00%)
      		10M
      NRZONeuRizer Ltd
      AUD 0.001
      (-50.00%)
      		1.01M
      DTIDTI Group Limited
      AUD 0.008
      (-38.46%)
      		196.84k
      PNTOAPanther Metals Ltd
      AUD 0.002
      (-33.33%)
      		47k
      ENTEnterprise Metals Limited
      AUD 0.003
      (-25.00%)
      		67.52k
      EATEntertainment Rewards Ltd
      AUD 0.003
      (-25.00%)
      		768.35k
      GCMGreen Critical Minerals Ltd
      AUD 0.019
      (5.56%)
      		106.09M
      ROGRed Sky Energy Limited
      AUD 0.0095
      (-9.52%)
      		68.79M
      IMUImugene Limited
      AUD 0.039
      (4.00%)
      		43.71M
      BRNBrainchip Holdings Ltd
      AUD 0.41
      (-5.20%)
      		27.13M
      TMGTrigg Minerals Ltd
      AUD 0.045
      (4.65%)
      		22.66M

      Discussion

      View Full Feed
      kthomp19 kthomp19 2 minutes ago
      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165986962 It has been 39 months since this post and you still haven't filed that lawsuit yet .

      I'm not holding my breath.

      The same applys to KTs senior cramdown.

      Yeah, it's "my" cramdown. Giv
      AIG
      Numonics Numonics 2 minutes ago
      https://youtu.be/o6fE45Bq4HY?si=zd5oP6Bw_8OGrT9Q
      FMCC
      hssbwwmp hssbwwmp 3 minutes ago
      Anyone able to get into the EXXE Group website? I tried a couple times over past couple of days and won't load. Did they close up shop?
      AXXA
      Numonics Numonics 3 minutes ago
      https://youtu.be/o6fE45Bq4HY

      In this exclusive conference call, Tim Pagliara and Grant Stark from CapWealth joined Ed Groshans of Compass Point to discuss the future of Government-Sponsored Enterprises (GSEs), including Fannie Mae and Freddie
      FMCC
      Hikerbc Hikerbc 4 minutes ago
      Masked Investor says GME Trade near 30.50 before it heads back up; even 29.50 is possible >

      Squeeze is near, but when , in a few days or three weeks ?

      HK
      GME
      Hikerbc Hikerbc 6 minutes ago
      AMC Heaviest Shorted stock in History, according to a youtuber.
      And is the main vehicle to control price for GME and a variety of other shorted stocks as well.

      He claims upon Squeeze, AMC will go much higher than GME.

      Something to think about
      AMC GME
      CanItBThisEZ2Make CanItBThisEZ2Make 6 minutes ago
      BEST SELLERS RANK (BSR) IS 334 3 Estimated Sold on Amazon Since JAN 1 - 1ST Quarter 2025
      https://investorshub.advfn.com/uimage/uploads/2024/4/24/cnxttVOS_5G_GIF.gif
      https://www.amazon.com/Vos-RDGL5GX55-B-01-VOS-5G-Dongle/dp/B0C66KHZLP

      NOTE: In theory, when BSR Value Decr
      SRMX
      kthomp19 kthomp19 6 minutes ago
      Things are going to change- I can feel it.

      You're a driver, you're a winner?
      FNMA
      maddyandboomer maddyandboomer 6 minutes ago
      CMON...There is no rhyme or reason?..that's BS and you know it....the o/s is 5x what it was a few years ago and this has been diluted exponentially and add in the company has not delivered on anything is why this is in the trips ...
      AXXA
      EarningsCentral EarningsCentral 6 minutes ago
      RGP
      Craig305 Craig305 7 minutes ago
      If Sofpulse was patent infringing on BIEL then BIEL would have counter sued after ENDV's lawsuit against BIEL failed. They are not infringing on each other. 
      The signals are not identical.
      You posted earlier that they are. They are not. Sofpulse has a stronger and deeper penetration. T
      ENDV
      kthomp19 kthomp19 7 minutes ago
      Yes, because that is what you expect of OTHERS.

      I disabused myself of that expectation long ago. The vast majority of the posters here, at least by post volume, are not interested in good faith discussions but instead ad hominems and inflated price estimates with no rigorous logic or
      FNMA
      kthomp19 kthomp19 7 minutes ago
      Keep in mind, I am basing this on my investment position. Everyone is different. I am not saying 5-30X of current 2025 prices or anyone else's cost basis, just that I am up 2X and I can see getting to 5X-30X over the next few years. Yes, I calculate many scenarios with senior conversion, warrant exe
      FMCC FNMAS
      kthomp19 kthomp19 7 minutes ago
      C'mon, you know as well as the rest of us that common shareholders DO HAVE rights to receive their share of profits

      The original SPSPAs subordinated the liquidation and dividend rights of the juniors and commons to the seniors and the NWS cemented that in place in perpetuity. Once eve
      FNMA
      kthomp19 kthomp19 7 minutes ago
      Your autosignature and your previous comments disagree with you. "File your own lawsuit or shut up" are the exact words used. This makes you a hypocrite. Or maybe you don't know what "per se" means?

      There are two types of people:
      1) Those who can infer conclusions from incomp
      FNMA
      kthomp19 kthomp19 8 minutes ago
      Kthomp has been an advocate of the coercive cramdown for a while

      No. You are making the same mistake as Rodney, which is conflating desire with expectation.

      I do not want Treasury to convert its seniors to commons, but I expect it. There is a huge difference there.
      DJT
      trunkmonk trunkmonk 8 minutes ago
      He is full of it, all over the spectrum. SM had him on a string. Thompson sleazed her way today?
      FNMA
      kthomp19 kthomp19 8 minutes ago
      Also, I think it more likely that the juniors will be converted to help with the cap requirement and the legacy stockholders would not have to rely on the kindness of strangers to the tune of $33B (which would get you the biggest, or second biggest, house in Hyattsville for sure.

      Ple
      FNMA
      kthomp19 kthomp19 8 minutes ago
      Because my post was before his latest tweet re price (or if it was it was before I saw it).

      I see. Ackman's tweet was on December 30 while your post was yesterday; I didn't realize you hadn't read it yet.

      The current price reflects the uncertainty of the fate of the sen
      FNMA
      YouShouldKnow YouShouldKnow 8 minutes ago
      Novel Hybrid Spun Silk Yarn Developed From Eri And Mulberry Silks Under Industrial Level And Its Characterizations

      https://www.tandfonline.com/doi/full/10.1080/15440478.2024.2445567#d1e141 Published Online: 30 Dec 2024
      KBLB
      kthomp19 kthomp19 8 minutes ago
      anyone saying recap and relist doesn't know what they're talking about. It's release, relist THEN recap (if necessary.)

      That makes no sense.

      The entire reason FnF are still in conservatorship is because they don't have enough regulatory (core, Tier 1, CET1) capital to n
      FNMA
      kthomp19 kthomp19 8 minutes ago
      If the GSE’s are released then dividends will be turned on automatically for JPS. It might take some time for commons to see dividends turned back on if they even do? That has not been addressed yet. If they do, would divs be turned on before or after an IPO of common??

      Just about the
      FNMA
      kthomp19 kthomp19 8 minutes ago
      Since you're so hung up on the AIG senior pref conversion mantra, why leave out the part about how the common share holders were issued warrants to purchase AIG stock at a certain price levels for 10 years to prevent dilution of common share price?

      Those warrants sure did a great job
      AIG
      dinogreeves dinogreeves 9 minutes ago
      They promoted someone from inside to a Senior Accounting Officer, he was awarded company stock, he was promoted on November 27th. Next PR will be new CFO, then earnings date will be announced for fiscal year or February 25th we will see 3 filings back to back. They are probably going to drag this
      SMCI
      TheHound TheHound 10 minutes ago
      It’s just a question of what it does when it gets there…

      That’s easy. Profit taking i.e. liquidity.

      It eventually goes higher. :-)
      XRPUSD

      Your Recent History

      ASX
      CUV
      Clinuvel Pharmaceuticals
      EU
      LITM
      iShares Lithium and Batt...
      BOV
      FLRY3M
      FLEURY ON
      LSE
      0EPY
      Philipp Holzmann Ag Il
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads